What a week for Protagonist Therapeutics! Protagonist received three exciting industry recognitions highlighting our innovation and business performance. With two FDA-approved, first-in-class peptidic medicines, #ICOTYDE™ and #MIMRYLO™ and a growing pipeline of differentiated peptide therapeutics, we continue to build on our successes as we advance new treatment options for patients. 🏆 TIME Best Inventions of 2026: ICOTYDE™ (icotrokinra), jointly discovered by Protagonist and Johnson & Johnson, was named one of TIME's Best Inventions of 2026. 🏆 Newsweek's America's Greatest Mid-Market Companies 2026: Protagonist was recognized for its strong business performance and continued growth. 🏆 Fierce Innovation Awards: Protagonist was named a finalist in the Biotech Innovation category of the 2026 Fierce Innovation Awards. Thank you, Fierce Life Sciences Events, for this recognition! #PTGX #FierceInnovator #Biotechnology #Innovation #PeptideTherapeutics

We are thrilled to share that ICOTYDE® (icotrokinra) has been named one of TIME Magazine's Best Inventions of 2026 in the Medical & Healthcare category! Jointly discovered by Protagonist Therapeutics and Johnson & Johnson scientists, ICOTYDE is the first and only targeted oral peptide therapy that selectively blocks the IL-23 receptor, offering a new oral treatment option for patients with moderate-to-severe plaque psoriasis. This recognition is a testament to the years of dedication, scientific innovation and hard work from the teams at Protagonist and Johnson & Johnson who helped bring ICOTYDE from discovery to patients. Read more: tinyurl.com/TIMEbestinventio… #TIMEBestInventions #ICOTYDE #PeptideInnovation

Protagonist Therapeutics is pleased to announce publication of the primary data from the pivotal Phase 3 VERIFY study of rusfertide in the Journal of Clinical Oncology. These data continue the momentum from the Plenary Presentation at #ASCO25. #PolycythemiaVera patients on rusfertide in the VERIFY study maintained hematocrit control, experienced a reduced phlebotomy burden, and noted improvements in fatigue and other patient reported outcomes. Read the publication: ascopubs.org/doi/10.1200/JCO…

New two-year Phase 3 data for ICOTYDE® (icotrokinra) were presented today by Johnson & Johnson at #EADV2026, supporting ICOTYDE’s potential as a first-line systemic therapy and targeted oral treatment option for patients with difficult-to-treat psoriasis who need to move beyond topical therapy. The Protagonist team is excited to be at EADV celebrating this achievement while connecting with KOLs and investigators about what’s next: advancing our IL-17 antagonist, PN-881, toward a planned Phase 2b psoriasis study in early 2027. Read more: tinyurl.com/6spcd9ac #ICOTYDE #Psoriasis #PeptideTherapeutics

MIMRYLO™ (rusfertide) has been approved in the United Arab Emirates for adults with Polycythemia Vera (PV). The Protagonist team is very pleased to see MIMRYLO reaching more patients around the world. #PolycythemiaVera #RareDisease #BloodCancer tinyurl.com/bderkhee

This week, the European Commission approved ICOTYDE™ (icotrokinra) for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Following approvals in the U.S. and China, European approval represents another important step in the global expansion of ICOTYDE — and further demonstrates the potential of targeted oral peptides to become an important new therapeutic option for patients worldwide. ema.europa.eu/en/medicines/h… #ICOTYDE #PeptideTherapeutics #PTGX

With two FDA-approved medicines from our peptide platform in 2026 and a growing pipeline of wholly owned programs, Protagonist is entering an exciting new phase. CEO Dinesh V. Patel is in New York City this week for two investor conferences. Tune in to hear his perspective on what’s next for Protagonist. Citi Biopharma Back to School Conference: Fireside Chat Day/Time: Today, September 9 at 10:40 AM ET Watch the replay: tinyurl.com/35wcj5pw 2026 Cantor Global Healthcare Conference: Fireside Chat Day/Time: Thursday, September 10 at 10:20 AM ET Webcast: tinyurl.com/4uv35drn

Press release | Protagonist Therapeutics Announces $300 Million Share Repurchase Program Read more: feeds.issuerdirect.com/news-…

The FDA approval of MIMRYLO™ (rusfertide) shows what strong partnerships make possible. Protagonist CEO Dinesh Patel and EVP of Business Development Carter King reflect on how Protagonist and Takeda brought complementary strengths to a shared goal: bringing a first-in-class new medicine to patients who need it. #PTGX #Biotech #Partnership

The FDA approval of MIMRYLO™ (rusfertide) marks the culmination of more than a decade of work at Protagonist. Members of our team reflect on the journey and the patients, investigators, partners, and colleagues who helped make it possible. #PTGX #FDAApproval #PV

Today, we're proud to announce that the U.S. FDA has approved MIMRYLO™ (rusfertide), the first and only hepcidin mimetic peptide therapy approved for the treatment of erythrocytosis in adults with polycythemia vera (#PV), offering a novel mechanism to maintain hematocrit control, meaningfully reduce phlebotomy burden, and improve fatigue. This achievement represents the successful outcome of more than 14 years of scientific innovation and dedication. MIMRYLO marks the second FDA approval after ICOTYDE™ in 2026 for Protagonist. This is a testament to our emerging leadership in peptide therapeutics and our ability to consistently deliver innovative medicines addressing unmet needs for patients. We would like to express our sincere gratitude to the Protagonist employees, our partner Takeda, research collaborators, clinical investigators, and patients who made this defining moment possible. Investor call: Monday, August 31st at 8:30 am ET. Read the full announcement for more details: feeds.issuerdirect.com/news-…

China’s drug regulator has approved #ICOTYDE for moderate-to-severe plaque psoriasis. ICOTYDE continues to demonstrate the power of our peptide discovery platform and long-term collaboration with Johnson & Johnson. With approvals now in the U.S. and China, we look forward to the European Commission’s decision and the potential to bring this differentiated oral therapy to more patients globally. finance.yahoo.com/healthcare… #Psoriasis #IL23 #OralPeptides

On Friday, @ProtagonistCEO Dinesh Patel joined @SchwabNetwork #NextGenInvesting live to discuss peptides, obesity, and biopharma disruption. Watch it here: schwabnetwork.com/video/prot… #schwabnetwork

Catch CEO Dinesh Patel today live on Schwab Network around 1:35 ET! schwabnetwork.com/ #PTGX #SchwabNetwork #NextGenInvesting

Today, ICOTYDE™ was nominated for the 2026 #PrixGalien USA Award for Best Pharmaceutical Product. This recognition by @GalienFdn highlights the scientific innovation behind the first and only FDA-approved targeted oral peptide designed to block the IL-23 receptor, bringing a novel plaque psoriasis treatment approach that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill. We’re gratified to see an innovation that began at Protagonist being recognized among this year's nominees and congratulate our colleagues at Johnson & Johnson, the Protagonist team, clinical investigators, and the patients who helped make this possible. #PeptideTherapeutics #DrugDiscovery #Innovation prnewswire.com/news-releases…

News: Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update Read more in our press release: tinyurl.com/5awxhatt

This Psoriasis Action Month, we recognize people living with #psoriasis and the clinicians, researchers, and advocates working to advance care. Protagonist is proud of the role our peptide technology platform played in ICOTYDE™, jointly discovered by Protagonist and Johnson & Johnson scientists and now approved by the FDA for moderate-to-severe plaque psoriasis. Innovation matters most when it reaches patients. #PTGX #PsoriasisActionMonth